Dna-pk inhibitors
US-2017258789-A1 · Sep 14, 2017 · US
US8993753B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8993753-B2 |
| Application number | US-201414154441-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 14, 2014 |
| Priority date | Aug 6, 2009 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a process for the stereoselective preparation of compounds of formulae (1A) and (1B) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.
Opening claim text (preview).
The invention claimed is: 1. A compound of formula (13) as well as the physiologically acceptable salts thereof with inorganic or organic acids and bases.
Drugs for immunological or allergic disorders · CPC title
Antineoplastic agents · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
Drugs for disorders of the respiratory system · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.